Biomerica Posts Encouraging Results From InFoods Study As Irritable Bowel Syndrome Treatment
Biomerica Inc (NASDAQ: BMRA) has announced topline results from its InFoods IBS diagnostic-guided therapy (DGT) endpoint clinical trial.
The trial showed statistically significant improvements in multiple endpoints in the Intent-to-Treat population.
The InFoods DGT uses a simple blood test to identify patient-specific foods that may alleviate Irritable Bowel Syndrome (IBS) symptoms such as pain, bloating, diarrhea, and constipation when removed from the diet.
Related: Biomerica's Shares Gain As Its Colon Disease Screening Test Goes For Sale At Walmart Online.
The InFoods IBS DGT works by identifying above normal immunoreactivity to specific foods in patients. Food identified as positive is removed from the diet for the patient to feel better.
Biomerica plans to meet and work with the FDA to design a final pivotal trial focused on the endpoint(s) that show the greatest improvement.
The pivotal trial protocol is expected to be substantially similar to the completed endpoint trial, with more patients participating.
Biomerica is also discussing opportunities to commercialize the InFoods IBS DGT before FDA clearance as a Laboratory Developed Test service offered through a CLIA laboratory and a CE Marked product in Europe or other countries.
Price Action: BMRA shares are down 4.57% at $4.07 during the market session on the last check Tuesday.
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
